Archives
-
Oleanolic Acid, FXR, and Cholestatic Liver Injury
2026-10-07
A 2024 study links oleanolic acid-induced cholestatic injury to impaired FXR-regulated bile acid efflux and loss of hepatocyte tight-junction integrity. Its combined transporter, structural, and pharmacological evidence places FXR signaling at the intersection of bile acid handling and epithelial barrier disruption, while also defining important limits for interpreting FXR agonist studies.
-
Affordable GRO-seq for Bread Wheat Nascent RNA
2026-10-07
Chen et al. describe a more cost-efficient Global Run-On sequencing (GRO-seq) framework for profiling nascent transcription in allohexaploid bread wheat. Its central innovation is integrating rRNA depletion into the workflow, which the authors report increased the proportion of valid data by 20 times and enabled enhancer RNA analysis in a complex plant genome.
-
Annexin V-Cy5/DAPI Apoptosis Kit: Reading Cell Death
2026-10-06
The Annexin V-Cy5/DAPI Apoptosis Kit provides a two-dimensional view of phosphatidylserine exposure and membrane integrity. This article explains how to interpret that apoptosis detection kit in the context of P2RX1 signaling, mitochondrial dysfunction, and tyrosine kinase inhibitor responses in Ph+ ALL.
-
Cyanin Chloride in a Psoriasis Cell Model
2026-10-06
A 2024 study examined cyanin chloride in chemical antioxidant assays, an LPS-stimulated macrophage model, and a cytokine-induced HaCaT keratinocyte model of psoriasis. Its main contribution was linking reduced inflammatory signaling, including STAT3 phosphorylation, with barrier-related outcomes such as transepithelial electrical resistance and filaggrin expression, while remaining limited to preclinical cell-based evidence.
-
LRPPRC–Dasatinib Synergy and Dual OXPHOS Disruption
2026-10-05
A 2026 study reports that dasatinib synergizes with LRPPRC inhibition in cancer cell models by disrupting complementary oxidative phosphorylation programs. The proposed mechanism links dasatinib to nuclear-encoded OXPHOS suppression and LRPPRC inhibition to mitochondrial-genome effects, providing a rationale for biomarker-guided combination research while remaining preclinical.
-
Aprotinin and the Translational Logic of Protease Control
2026-10-04
A source-grounded perspective on Aprotinin as a reversible serine protease inhibitor, using the GRO-seq literature to frame assay quality, causal interpretation, translational relevance, and responsible product selection.
-
Cy5 Amine (Non-Sulfonated): Product Overview
2026-10-03
Cy5 amine (non-sulfonated), SKU A8143, is a supplier-listed amine-functionalized cyanine dye for conceptual fluorescent labeling applications. No matched research paper was available, so performance claims and application-specific conclusions cannot be independently assessed.
-
EZ Cap™ Human PTEN mRNA: Mechanism & Use
2026-10-01
EZ Cap™ Human PTEN mRNA (ψUTP) is an in vitro transcribed mRNA reagent encoding human PTEN with Cap 1, pseudouridine triphosphate, and a poly(A) tail. Its design supports mRNA stability enhancement, translation, and experimental restoration of PTEN-mediated PI3K/Akt signaling pathway inhibition, but nanoparticle delivery and functional outcomes require separate validation.
-
Verapamil Targets Txnip in Osteoporosis
2026-10-01
A 2025 Journal of Orthopaedic Translation study identifies Txnip as a mechanistic link between verapamil exposure and abnormal bone remodeling. Human genetic data, cell assays, transcriptomics, and an ovariectomy mouse model together suggest that verapamil can reduce bone loss through ChREBP–Txnip signaling in osteoclasts and osteoblasts, while important translational limitations remain.
-
Metformin Hydrochloride in Whole-Blood Assays
2026-10-01
Use Metformin Hydrochloride as a tunable metabolic intervention rather than a single-purpose glucose reagent. This guide connects AMPK-centered mechanism studies with standardized whole-blood cytokine assays, emphasizing formulation, donor controls, timing, and interpretation.
-
Naloxone hydrochloride in Opioid Research
2026-09-30
Learn how to deploy naloxone hydrochloride as a controlled opioid-receptor perturbation tool across behavioral, cellular, and immune assays. This guide connects withdrawal-anxiety research with practical stock preparation, assay controls, troubleshooting, and translational interpretation.
-
MOG (35-55) Peptide: EAE Assay Reliability
2026-09-29
This scenario-driven guide explains how MOG (35-55) Peptide, SKU A8306, can support controlled EAE induction and complementary neuroinflammation or cell-viability workflows. It covers formulation, dosing, assay controls, interpretation limits, and practical criteria for selecting a reliable myelin oligodendrocyte glycoprotein peptide.
-
Mc-Val-Cit-PABC-PNP Workflow Guide
2026-09-29
Mc-Val-Cit-PABC-PNP is a cathepsin-cleavable peptide linker for antibody-drug conjugate workflows that require enzyme-responsive payload release in lysosomal environments. It is intended for controlled scientific research, with strong DMSO solubility but poor suitability for water- or ethanol-based handling, diagnostic use, or therapeutic administration.
-
CTCF Maintains Centromere Function in Mitosis
2026-09-28
The reference study uses rapid, inducible CTCF degradation to show that CTCF preserves centromere organization, metaphase plate geometry, mitotic fidelity, and post-mitotic nuclear shape. Its results distinguish CTCF loss from simple failure to recruit CENP-E and instead support a centromere-maintenance model related to chromosome tension and cohesin-associated architecture.
-
PTEN mRNA Nanoparticles Reverse Trastuzumab Resistance
2026-09-28
Dong and colleagues developed tumor-microenvironment-responsive nanoparticles for systemic PTEN mRNA delivery, aiming to restore PTEN expression and suppress PI3K/Akt signaling in trastuzumab-resistant breast cancer. The study links pH-triggered carrier changes to tumor-cell uptake and improved antitumor activity in experimental models, while leaving clinical efficacy and broader transferability to be established.